CClinicalTrials.gg
CompletedNCT05614713Updated Nov 14, 2022

Effect of Sensory Integration Therapy on Balance and Functional Mobility

An interventional study of Selected physical therapy program and Modified physical therapy program to increase sensory input in Cerebral Palsy, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 6 Years to 10 Years. Per ClinicalTrials.gov, last updated 2022-11-14.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Sep 2021, registered Nov 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
6 Years to 10 Years
Sex
All
01

Study summary

Purpose: to investigate the effect of sensory integration therapy on balance and functional mobility in children with spastic diplegic cerebral palsy. Methods: children with spastic cerebral palsy, the children were assigned to a control group and a study group. Balance was assessed using the Biodex balance system and functional mobility was assessed using the Timed Up and Go test.

Read the detailed description

Purpose: to investigate the effect of sensory integration therapy on balance and functional mobility in children with spastic diplegic cerebral palsy. Methods: children with spastic cerebral palsy, the children were assigned to a control group and a study group. Balance was assessed using the Biodex balance system and functional mobility was assessed using the Timed Up and Go test. The control group received selected physical therapy, while the study group received the previously mentioned selected physical therapy program modified to increase sensory input. Treatment sessions for both groups were conducted for both groups for 1 hour once a day, three times per week for two successive months.

02

Conditions studied

  • Cerebral Palsy

Browse trials for

03

In context

Cerebral Palsy

1,853 studies on the registry are indexed under Cerebral Palsy; 435 are open to participants now.

This study's enrollment of 40 is above the median of 33 across 1,368 interventional studies indexed under Cerebral Palsy.

Browse Cerebral Palsy studies →

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Ages from 6-10 years old. The degree of spasticity was 1 to 1+ Level II according to the Gross motor function classification system

Exclusion criteria

Exclusion Criteria:

Visual or auditory problems. Fixed deformities of lower limbs.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Study group

    received a modified selected physical therapy program to increase sensory input.

    Procedure: Modified physical therapy program to increase sensory input

  • Active comparator
    Control group

    received a selected physical therapy

    Procedure: Selected physical therapy program

Interventions

  • ProcedureSelected physical therapy program

    Gait training and balance training

  • ProcedureModified physical therapy program to increase sensory input

    Gait training and balance training using sensory stimulating matts

06

What researchers measure

Primary outcomes

  1. Assessment of balance

    Assessment by using Biodex Balance System

    Time frame: After 2 months of intervention

  2. Assessment of functional mobility

    Assessment by using the Timed Up and Go test

    Time frame: After 2 months of intervention

07

Study locations

1 site
  • Faculty of physical therapy, Cairo university
    Cairo, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05614713
Lead sponsor
Cairo University
Responsible party
Mai Elsayed Abbass (Mai Elsayed Abbass, Cairo University) — Principal investigator
First posted
Nov 14, 2022
Start date
Sep 1, 2021
Primary completion
Feb 1, 2022
Completion
Feb 27, 2022
Last update
Nov 14, 2022

Study contacts

Mai E Abbass, Ph.D.
study director · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion